
Minerva Neurosciences Market Cap | NERV
As of November 22, 2026 Minerva Neurosciences has a market cap of $ 17.2 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Minerva Neurosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.8 M | 13.6 M | 47.3 M | 9.93 M | 4.28 M | 134 M | 277 M | 261 M | 230 M | 326 M | 122 M | 55.7 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 326 M | 4.28 M | 129 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Annexon
ANNX
|
769 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
1.91 B | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
109 K | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
3.19 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
126 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
43.8 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
24.6 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
353 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
25 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
13.5 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
855 M | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
1.4 B | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
1.4 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
43.9 B | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
7.1 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
117 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
184 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
1.02 B | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
528 K | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
148 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
28 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
851 K | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
8.96 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
450 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
17.7 M | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
548 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
3.35 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
48.1 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
114 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
1.08 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
39.9 M | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
52.7 M | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
127 M | - | - | $ 127 M | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
52.7 M | - | - | $ 231 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
4.11 B | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Gilead Sciences
GILD
|
183 B | $ 166.01 | -0.31 % | $ 207 B | ||
|
Assembly Biosciences
ASMB
|
308 M | $ 22.14 | -1.6 % | $ 248 M | ||
|
Dynavax Technologies Corporation
DVAX
|
1.73 B | - | - | $ 2.02 B | ||
|
Turning Point Therapeutics
TPTX
|
2.35 B | - | -0.13 % | $ 3.73 B | ||
|
Orgenesis
ORGS
|
1.45 M | - | -33.86 % | $ 61.2 M | ||
|
TCR2 Therapeutics
TCRR
|
57.9 M | - | - | $ 58.1 M |